Functional heterogeneity of osteopontin isoforms in non-small cell lung cancer

Journal of Thoracic Oncology

Volumn 5, Issue 10, 2010, Pages 1516-1523

  Goparaju, Chandra M V ^a   Pass, Harvey I ^a   Blasberg, Justin D ^a   Hirsch, Nathalie ^a   Donington, Jessica S ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Epithelial mesenchymal transition; mRNA isoforms; Non small cell lung cancer; Osteopontin; Tumor progression

Indexed keywords

COMPLEMENTARY DNA; OSTEOPONTIN; OSTEOPONTIN A; OSTEOPONTIN B; OSTEOPONTIN C; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CELL INVASION; CELL PROLIFERATION; COLONY FORMATION; CONTROLLED STUDY; ENZYME ACTIVITY; EPITHELIAL MESENCHYMAL TRANSITION; GENE AMPLIFICATION; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; METASTASIS POTENTIAL; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 77958182984     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181eba6bd     Document Type: Article

References (24)

1. Ashkar S, Weber GF, Panoutsakopoulou V, et al. Eta-1 (osteopontin): an early component of type-1 (cell-mediated) immunity. Science 2000;287:860-864. (Pubitemid 30084330)
2. Liaw L, Birk DE, Ballas CB, et al. Altered wound healing in mice lacking a functional osteopontin gene (spp1). J Clin Invest 1998;101: 1468-1478. (Pubitemid 28166845)
3. Das R, Philip S, Mahabeleshwar GH, et al. Osteopontin: it's role in regulation of cell motility and nuclear factor kappa B-mediated urokinase type plasminogen activator expression. IUBMB Life 2005;57:441-447. (Pubitemid 41073126)
4. Denhardt DT, Guo X. Osteopontin: a protein with diverse functions. FASEB J 1993;7:1475-1482. (Pubitemid 24003267)
5. Behrend EI, Craig AM, Wilson SM, et al. Reduced malignancy of ras-transformed NIH 3T3 cells expressing antisense osteopontin RNA. Cancer Res 1994;54:832-837.
6. Gardner HA, Berse B, Senger DR. Specific reduction in osteopontin synthesis by antisense RNA inhibits the tumorigenicity of transformed Rat1 fibroblasts. Oncogene 1994;9:2321-2326. (Pubitemid 24228683)
7. O'Regan A, Berman JS. Osteopontin: a key cytokine in cell-mediated and granulomatous inflammation. Int J Exp Pathol 2000;81:373-390. (Pubitemid 32291179)
8. Young MF, Kerr JM, Termine JD, et al. cDNA cloning, mRNA distribution and heterogeneity, chromosomal location, and RFLP analysis of human osteopontin (OPN). Genomics 1990;7:491-502.
9. Hu Z, Lin D, Yuan J, et al. Overexpression of osteopontin is associated with more aggressive phenotypes in human non-small cell lung cancer. Clin Cancer Res 2005;11:4646-4652. (Pubitemid 41557181)
10. Shijubo N, Uede T, Kon S, et al. Vascular endothelial growth factor and osteopontin in stage I lung adenocarcinoma. Am J Respir Crit Care Med 1999;160:1269-1273. (Pubitemid 29487470)
11. Donati V, Boldrini L, Dell'Omodarme M, et al. Osteopontin expression and prognostic significance in non-small cell lung cancer. Clin Cancer Res 2005;11:6459-6465. (Pubitemid 41338982)
12. Blasberg JD, Goparaju CM, Pass HI, et al. Lung cancer osteopontin isoforms exhibit angiogenic functional heterogeneity. J Thoracic Cardiovasc Surg 2010;139:1587-1593.
13. Irizarry RA, Bolstad BM, Collin F, et al. Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res 2003;31:e15.
14. Lee JM, Dedhar S, Kalluri R, et al. The epithelial-mesenchymal transition: new insights in signaling, development, and disease. J Cell Biol 2006;172:973-981.
15. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001;25:402-408. (Pubitemid 34164012)
16. Le QT, Chen E, Salim A, et al. An evaluation of tumor oxygenation and gene expression in patients with early stage non-small cell lung cancers. Clin Cancer Res 2006;12:1507-1514.
17. Zhang J, Takahashi K, Takahashi F, et al. Differential osteopontin expression in lung cancer. Cancer Lett 2001;171:215-222. (Pubitemid 32772809)
18. Bogenrieder T, Herlyn M. Axis of evil: molecular mechanisms of cancer metastasis. Oncogene 2003;22:6524-6536. (Pubitemid 37372332)
19. Saitoh Y, Kuratsu J, Takeshima H, et al. Expression of osteopontin in human glioma. Its correlation with the malignancy. Lab Invest 1995;72:55-63.
20. Mirza M, Shaughnessy E, Hurley JK, et al. Osteopontin-c is a selective marker of breast cancer. Int J Can 2008;122:889-897.
21. He B, Mirza M, Weber GF. An osteopontin splice variant induces anchorage independence in human breast cancer cells. Oncogene 2006; 25:2192-2202.
22. Yilmaz M, Christofori G, Lehembre F. Distinct mechanisms of tumor invasion and metastasis. Trends Mol Med 2007;13:535-541. (Pubitemid 350123764)
23. Hulit J, Suyama K, Chung S, et al. N-cadherin signaling potentiates mammary tumor metastasis via enhanced extracellular signal-regulated kinase activation. Cancer Res 2007;67:3106-3116. (Pubitemid 46724847)
24. Agiostratidou G, Hulit J, Phillips GR, et al. Differential cadherin expression: potential markers for epithelial to mesenchymal transformation during tumor progression. J Mammary Gland Biol Neoplasia 2007;12:127-133. (Pubitemid 47215430)